MCID: NRL005
MIFTS: 65

Neurilemmoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neurilemmoma

MalaCards integrated aliases for Neurilemmoma:

Name: Neurilemmoma 12 54 60 45 15 74
Schwannoma 12 54 30 56 6 15 17
Benign Schwannoma 54 60 74
Peripheral Fibroblastoma 54 60
Neurilemoma 54 60
Psammomatous Schwannoma 12
Neurolemmoma 54

Characteristics:

Orphanet epidemiological data:

60
benign schwannoma
Prevalence: 1-9/100000 (Europe);

Classifications:

Orphanet: 60  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3192
MeSH 45 D009442
NCIt 51 C3269
SNOMED-CT 69 985004
UMLS via Orphanet 75 C0027809 C0854906
Orphanet 60 ORPHA252164

Summaries for Neurilemmoma

NIH Rare Diseases : 54 A schwannoma is a tumor of the peripheral nervous system or nerve root. A schwannoma develops from cells called Schwann cells, a type of cell that wraps itself around peripheral nerves and provides protection and support. Schwannomas are almost always benign (not cancerous), but rarely, may become cancerous (a malignant schwannoma). Symptoms of a schwannoma may be vague and will vary depending on its location and size, but may include a lump or bump that can be seen or felt, pain, muscle weakness, tingling, numbness, hearing problems, and/or facial paralysis. Sometimes schwannomas do not cause any symptoms. Schwannomas usually develop in otherwise healthy people for unknown reasons. In some cases, a schwannoma is caused by a genetic disorder such as neurofibromatosis 2 (NF2), schwannomatosis, or Carney complex. People with these genetic disorders usually have more than one schwannoma. Schwannomas may be diagnosed using imaging studies. A biopsy may confirm the diagnosis. Treatment of benign schwannomas may involve surgery to remove the tumor. Treatment of malignant schwannomas may include both surgery and radiation therapy.

MalaCards based summary : Neurilemmoma, also known as schwannoma, is related to neurilemmoma of the fifth cranial nerve and neurofibromatosis, type iv, of riccardi. An important gene associated with Neurilemmoma is SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), and among its related pathways/superpathways are ERK Signaling and Actin Nucleation by ARP-WASP Complex. The drugs Anti-Infective Agents and Gentamicins have been mentioned in the context of this disorder. Affiliated tissues include tongue, bone and colon, and related phenotypes are vestibular schwannoma and peripheral schwannoma

Wikipedia : 77 A schwannoma is a usually benign nerve sheath tumor composed of Schwann cells, which normally produce... more...

Related Diseases for Neurilemmoma

Diseases related to Neurilemmoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 577)
# Related Disease Score Top Affiliating Genes
1 neurilemmoma of the fifth cranial nerve 33.4 GFAP NF1 NF2 PRKAR1A
2 neurofibromatosis, type iv, of riccardi 33.2 KIT NF1 NF2 PDGFRA
3 neurofibromatosis, type ii 33.1 EZR MSN NF1 NF2
4 neurofibromatosis, type i 32.7 KIT NF1 PDGFRA
5 malignant triton tumor 32.6 NF1 S100B
6 schwannomatosis 1 32.4 NF2 SMARCB1
7 neurilemmomatosis 32.4 NF1 NF2 PRKAR1A SMARCB1
8 intraneural perineurioma 32.3 NF1 S100B SOX10
9 cellular schwannoma 31.8 NF1 NF2 NGFR S100B SOX10
10 plexiform schwannoma 31.5 ENO2 GFAP KIT NF1 NF2 NGFR
11 neurofibrosarcoma 31.2 NF1 NF2
12 malignant peripheral nerve sheath tumor 30.9 ACTC1 KIT NF1 NF2 PDGFRA S100B
13 spinal meningioma 30.8 ENO2 NF1 NF2 SOX10
14 meningioma, familial 30.7 ENO2 GFAP NF1 NF2 SMARCB1
15 perineurioma 30.6 KIT S100B VIM
16 plexiform neurofibroma 30.6 NF1 NF2
17 benign ependymoma 30.5 ENO2 GFAP NF2
18 gastrointestinal stromal tumor 30.4 ACTC1 ENO2 KIT NES NF1 PDGFRA
19 leiomyoma 30.2 ACTC1 KIT VIM
20 desmoid tumor 30.1 KIT PDGFRA
21 monosomy 22 30.0 NF2 SMARCB1
22 microcystic meningioma 30.0 ENO2 GFAP
23 pilocytic astrocytoma 30.0 GFAP NF1 SOX10
24 epithelioid malignant peripheral nerve sheath tumor 30.0 ENO2 NF1 S100B SMARCB1
25 neurofibroma 29.9 KIT NF1 NF2 PDGFRA S100B SOX10
26 granular cell tumor 29.9 ENO2 GFAP S100B VIM
27 angiolipoma 29.9 ACTC1 VIM
28 clear cell meningioma 29.9 GFAP VIM
29 cerebellopontine angle tumor 29.8 GFAP NF2 SMARCB1
30 neuroma 29.8 ENO2 GFAP NF2 S100B SMARCB1
31 amelanotic melanoma 29.8 KIT S100B VIM
32 embryonal sarcoma 29.8 KIT S100B VIM
33 cavernous hemangioma 29.8 KIT PDGFRA VIM
34 hemangioblastoma 29.7 ENO2 EZR GFAP S100B
35 clear cell sarcoma 29.7 ENO2 KIT S100B
36 traumatic brain injury 29.7 ENO2 GFAP S100B
37 brain injury 29.7 ENO2 GFAP S100B
38 malignant granular cell myoblastoma 29.7 ENO2 SOX10
39 pleomorphic adenoma 29.7 ACTC1 GFAP S100B VIM
40 hemangiopericytoma, malignant 29.7 ACTC1 NGFR S100B VIM
41 intravascular papillary endothelial hyperplasia 29.6 ACTC1 VIM
42 fibrous meningioma 29.6 NF2 S100B VIM
43 rhabdoid tumor predisposition syndrome 1 29.5 ACTC1 SMARCB1 VIM
44 cutaneous fibrous histiocytoma 29.5 ACTC1 S100B VIM
45 anaplastic ganglioglioma 29.5 ACTC1 GFAP NES
46 glomus tumor 29.4 ACTC1 ENO2 VIM
47 endometrial stromal sarcoma 29.4 ACTC1 KIT VIM
48 chordoma 29.4 GFAP PDGFRA S100B SMARCB1 VIM
49 oligodendroglioma 29.3 ENO2 GFAP PDGFRA S100B SOX10
50 spindle cell sarcoma 29.3 ACTC1 NF2 S100B VIM

Graphical network of the top 20 diseases related to Neurilemmoma:



Diseases related to Neurilemmoma

Symptoms & Phenotypes for Neurilemmoma

Human phenotypes related to Neurilemmoma:

60 33 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 vestibular schwannoma 60 33 hallmark (90%) Very frequent (99-80%) HP:0009588
2 peripheral schwannoma 60 33 hallmark (90%) Very frequent (99-80%) HP:0009593
3 abnormality of peripheral nervous system electrophysiology 60 33 hallmark (90%) Very frequent (99-80%) HP:0030177
4 scleral schwannoma 60 33 hallmark (90%) Very frequent (99-80%) HP:0100011
5 abnormal temporal bone morphology 33 hallmark (90%) HP:0009911
6 facial palsy 60 33 frequent (33%) Frequent (79-30%) HP:0010628
7 hearing abnormality 60 33 frequent (33%) Frequent (79-30%) HP:0000364
8 vertigo 60 33 frequent (33%) Frequent (79-30%) HP:0002321
9 allodynia 60 33 frequent (33%) Frequent (79-30%) HP:0012533
10 morphological abnormality of the central nervous system 60 33 occasional (7.5%) Occasional (29-5%) HP:0002011
11 intestinal polyposis 60 33 occasional (7.5%) Occasional (29-5%) HP:0200008
12 nasal polyposis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100582
13 abnormality of the liver 60 33 occasional (7.5%) Occasional (29-5%) HP:0001392
14 abnormality of the adrenal glands 60 33 occasional (7.5%) Occasional (29-5%) HP:0000834
15 abnormality of the larynx 60 33 occasional (7.5%) Occasional (29-5%) HP:0001600
16 abnormality of the breast 60 33 occasional (7.5%) Occasional (29-5%) HP:0000769
17 acute episodes of neuropathic symptoms 60 33 occasional (7.5%) Occasional (29-5%) HP:0003489
18 abnormality of the twelfth cranial nerve 60 33 occasional (7.5%) Occasional (29-5%) HP:0010826
19 abnormality of fibula morphology 33 occasional (7.5%) HP:0002991
20 abnormal parotid gland morphology 33 occasional (7.5%) HP:0000197
21 abnormal esophagus morphology 33 occasional (7.5%) HP:0002031
22 pain 60 Occasional (29-5%)
23 abnormality of the cranial nerves 60 Very frequent (99-80%)
24 abnormality of the fibula 60 Occasional (29-5%)
25 schwannoma 60 Very frequent (99-80%)
26 abnormality of parotid gland 60 Occasional (29-5%)
27 abnormality of esophagus morphology 60 Occasional (29-5%)
28 abnormality of the temporal bone 60 Very frequent (99-80%)
29 neurofibrosarcoma 60 Excluded (0%)

GenomeRNAi Phenotypes related to Neurilemmoma according to GeneCards Suite gene sharing:

27 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.45 PDGFRA
2 Decreased viability GR00221-A-1 10.45 PDGFRA PRKAR1A SMARCB1 KIT NF1
3 Decreased viability GR00221-A-2 10.45 PRKAR1A SMARCB1 NF1
4 Decreased viability GR00221-A-3 10.45 NF2 PDGFRA PRKAR1A SMARCB1
5 Decreased viability GR00221-A-4 10.45 PDGFRA PRKAR1A NF1
6 Decreased viability GR00301-A 10.45 KIT
7 Decreased viability GR00381-A-1 10.45 SMARCB1
8 Decreased viability GR00402-S-2 10.45 NF2 PDGFRA PRKAR1A SMARCB1 KIT NF1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.9 S100B SMARCB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.9 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.9 SOX10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.9 VIM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.9 SMARCB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.9 SOX10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.9 SMARCB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.9 VIM
17 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.9 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.9 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.9 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.9 SMARCB1 VIM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.9 SOX10 VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.9 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.9 VIM
24 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.9 SMARCB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.9 VIM
26 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.9 KIT VIM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.9 SOX10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.9 KIT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.9 SOX10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.9 S100B VIM
31 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.9 SOX10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.9 SOX10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.9 SOX10
34 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.9 SMARCB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.9 KIT S100B SMARCB1 SOX10 VIM
36 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.9 KIT
37 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.9 KIT
38 Increased proliferation GR00094-A 8.96 NF2 SMARCB1

MGI Mouse Phenotypes related to Neurilemmoma:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.35 ENO2 GFAP KIT NF1 NF2 NGFR
2 cellular MP:0005384 10.3 ACTC1 ENO2 GFAP KIT NF1 NGFR
3 growth/size/body region MP:0005378 10.29 ACTC1 ENO2 EZR GFAP KIT NF1
4 homeostasis/metabolism MP:0005376 10.27 ACTC1 GFAP KIT NF1 NF2 NGFR
5 cardiovascular system MP:0005385 10.22 ACTC1 GFAP KIT NF1 NGFR PDGFRA
6 mortality/aging MP:0010768 10.21 ACTC1 EZR GFAP KIT NF1 NF2
7 digestive/alimentary MP:0005381 10.19 EZR GFAP KIT NF1 NGFR PDGFRA
8 immune system MP:0005387 10.18 EZR GFAP KIT NF1 NF2 NGFR
9 embryo MP:0005380 10.13 KIT NF1 NF2 PDGFRA PRKAR1A SMARCB1
10 craniofacial MP:0005382 10.09 ENO2 KIT NF1 NF2 NGFR PDGFRA
11 integument MP:0010771 10.06 KIT NF1 NF2 NGFR PDGFRA PRKAR1A
12 muscle MP:0005369 10.06 ACTC1 GFAP KIT NF1 NGFR PDGFRA
13 nervous system MP:0003631 10.02 ENO2 GFAP KIT NF1 NF2 NGFR
14 normal MP:0002873 9.96 ACTC1 GFAP KIT MSN NF1 NGFR
15 neoplasm MP:0002006 9.91 KIT NF1 NF2 PDGFRA PRKAR1A SMARCB1
16 respiratory system MP:0005388 9.61 ENO2 KIT NF1 NF2 NGFR PDGFRA
17 pigmentation MP:0001186 9.55 KIT NF1 PDGFRA PRKAR1A SOX10
18 vision/eye MP:0005391 9.23 GFAP KIT NF1 NF2 NGFR PRKAR1A

Drugs & Therapeutics for Neurilemmoma

Drugs for Neurilemmoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
2 Gentamicins Phase 4,Not Applicable
3 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
4
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
5
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
6
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
7
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
8
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
9 Antineoplastic Agents, Hormonal Phase 3,Not Applicable
10 glucocorticoids Phase 3
11 Antiemetics Phase 3
12 Hormone Antagonists Phase 3
13 Peripheral Nervous System Agents Phase 3,Phase 2
14 Gastrointestinal Agents Phase 3,Not Applicable
15 Hormones Phase 3
16 Methylprednisolone Acetate Phase 3
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
18 Anti-Inflammatory Agents Phase 3,Phase 2
19 Protective Agents Phase 3
20 Neuroprotective Agents Phase 3
21 Autonomic Agents Phase 3
22 Prednisolone acetate Phase 3
23
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
24
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 5284616 6436030
25
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
26
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 70789204 6442177
27
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
28
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
29
Histamine Approved, Investigational Phase 2 51-45-6 774
30
Betahistine Approved, Investigational Phase 2 5638-76-6 2366
31
Lapatinib Approved March 2007, Investigational Phase 2,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
32
Lactitol Investigational Phase 2 585-88-6, 585-86-4 493591
33 Antibodies, Monoclonal Phase 2,Phase 1
34 Antineoplastic Agents, Immunological Phase 2,Phase 1
35 Antibodies Phase 2,Phase 1
36 Immunologic Factors Phase 2,Phase 1,Early Phase 1
37 Angiogenesis Inhibitors Phase 2,Phase 1
38 Immunoglobulins Phase 2,Phase 1
39 Angiogenesis Modulating Agents Phase 2,Phase 1
40 Immunosuppressive Agents Phase 2,Phase 1,Early Phase 1
41 Antibiotics, Antitubercular Phase 2,Phase 1,Early Phase 1
42 Antifungal Agents Phase 2,Phase 1,Early Phase 1
43 Endostatins Phase 2 71581480
44 Protein Kinase Inhibitors Phase 2,Early Phase 1
45 Imatinib Mesylate Phase 2 220127-57-1 123596
46 Analgesics Phase 2
47 Anti-Inflammatory Agents, Non-Steroidal Phase 2
48 Analgesics, Non-Narcotic Phase 2
49 Antipyretics Phase 2
50 Fibrinolytic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
3 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
4 Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery Completed NCT00438087 Phase 3 methylprednisolone
5 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
6 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Unknown status NCT02934256 Phase 2 Icotinib
7 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
8 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
9 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
10 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
11 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
12 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
13 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
14 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
15 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
16 Study of Aspirin in Patients With Vestibular Schwannoma Recruiting NCT03079999 Phase 2 Aspirin;Placebo
17 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
18 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
19 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
20 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT02129647 Phase 2 Axitinib
21 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
22 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
23 AM-125 in the Treatment of Acute Peripheral Vertigo Following Vestibular Schwannoma Resection Not yet recruiting NCT03908567 Phase 2 Intranasal Drug;Oral Tablet
24 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
25 Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
26 PTC299 for Treatment of Neurofibromatosis Type 2 Terminated NCT00911248 Phase 2 PTC299
27 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
28 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Completed NCT00030043 Phase 1
29 Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET Recruiting NCT03542773 Phase 1 18F-DCFPyL Injection
30 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
31 Indocyanine Green for Central Nervous System Tumors, Tumor Glow Enrolling by invitation NCT03262636 Phase 1 Indocyanine Green
32 Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
33 Vestibular Schwannoma and Psychological Factors Unknown status NCT01743248
34 Preoperative Vestibular Rehabilitation Effectiveness After Vestibular Schwannoma Surgery Unknown status NCT02275325 Not Applicable
35 Response Prediction After GKS in Patients With Vestibular Schwannoma Using DCE MR Imaging Unknown status NCT03097822
36 NF2 Natural History Consortium Unknown status NCT00004483
37 Taste Disorders in Middle Ear Disease and After Middle Ear Surgery Unknown status NCT01584011
38 Effect of Implant Position on Magnetic Resonance Image Distortion Unknown status NCT02246231 Not Applicable
39 Assessment of Volumetric Growth Rates of Spinal Intradural Extramedullary Schwannoma Completed NCT01951365
40 Role of Psychiatric Profile in Prehabituated Patients After Vestibular Schwannoma Surgery Completed NCT03638310 Not Applicable
41 Vestibular Evaluation After Vestibular Schwannoma Treatment Completed NCT03670589
42 WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data Completed NCT03210285
43 Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma Completed NCT02963896 Not Applicable gentamicin
44 Concentration and Activity of Lapatinib in Vestibular Schwannomas Completed NCT00863122 Early Phase 1 lapatinib
45 Alternative Treatment of Giant Spinal Schwannomas Completed NCT02494622
46 Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients Completed NCT01222728
47 Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach Completed NCT02309099 Not Applicable
48 Hippocampal Radiation Exposure and Memory Completed NCT00603694
49 Recovery of Visual Acuity in People With Vestibular Deficits Completed NCT00411216 Not Applicable
50 Analysis of NF2 Mutations in Radiation-Related Neural Tumors Completed NCT00340496

Search NIH Clinical Center for Neurilemmoma

Cochrane evidence based reviews: neurilemmoma

Genetic Tests for Neurilemmoma

Genetic tests related to Neurilemmoma:

# Genetic test Affiliating Genes
1 Schwannoma 30

Anatomical Context for Neurilemmoma

MalaCards organs/tissues related to Neurilemmoma:

42
Tongue, Bone, Colon, Thyroid, Brain, Prostate, Testes

Publications for Neurilemmoma

Articles related to Neurilemmoma:

(show top 50) (show all 3520)
# Title Authors Year
1
Schwannoma-Like Pleomorphic Adenoma: Two Cases and a Review of the Literature. ( 30968284 )
2019
2
De novo cavernous malformation arising in the wall of vestibular schwannoma following stereotactic radiosurgery: case report and review of the literature. ( 30430258 )
2019
3
MR imaging of vaginal cellular schwannoma. ( 30195699 )
2019
4
Successful Excision of Endobronchial Cellular Schwannoma With Right Lower Sleeve Lobectomy. ( 30205116 )
2019
5
Coexistent Vestibular Schwannoma and Creutzfeldt-Jakob Disease: Recognition and Infection Control. ( 30742601 )
2019
6
Occipital lobe epilepsy was presented in a patient with intracerebral schwannoma: a case report and literature review. ( 30232919 )
2019
7
Laparoscopic distal gastrectomy for gastric cancer with simultaneous resection of para-aortic schwannoma. ( 30714347 )
2019
8
Serum Levels of APRIL Increase in Patients with Glioma, Meningioma and Schwannoma ( 30909681 )
2019
9
Palisading and Verocay Body Prominent Orbital Leiomyosarcoma, Masquerading as a Schwannoma. ( 30326763 )
2019
10
Duodenal Schwannoma as a Rare Association With Membranous Nephropathy: A Case Report. ( 30454884 )
2019
11
Synchronous Presentation of a Cervical Spinal Schwannoma and Primary Progressive Multiple Sclerosis in a 65-year-old Man. ( 31093475 )
2019
12
Posterior Mediastinal Schwannoma (Neurilemmoma). ( 30832802 )
2019
13
Hybrid Neurofibroma/Schwannoma of the Orbit. ( 30856631 )
2019
14
Renal Oncocytoma and Retroperitoneal Ancient Schwannoma: A Benign Mimic of Metastatic Renal Cell Carcinoma. ( 30915254 )
2019
15
Hemorrhagic Spinal Schwannoma in Thoracolumbar Area with Total Paraplegia. ( 30719046 )
2019
16
Gastric hybrid schwannoma/perineurioma. ( 31068255 )
2019
17
Oral plexiform schwannoma: A case report and relevant immunohistochemical investigation. ( 30911392 )
2019
18
Plexiform Schwannoma of the Penis: A Rare Subtype of Genital Schwannoma. ( 31073418 )
2019
19
Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer. ( 30371596 )
2019
20
Improvement or Recovery From Sudden Sensorineural Hearing Loss With Steroid Therapy Does Not Preclude the Need for MRI to Rule Out Vestibular Schwannoma. ( 30807520 )
2019
21
Improvement or Recovery From Sudden Sensorineural Hearing Loss With Steroid Therapy Does Not Preclude the Need for MRI to Rule Out Vestibular Schwannoma. ( 31083098 )
2019
22
Acute sensorineural hearing loss in patients with vestibular schwannoma early after cyberknife radiosurgery. ( 30769220 )
2019
23
Sensorineural hearing loss in patients with vestibular schwannoma correlates with the presence of utricular hydrops as diagnosed on heavily T2-weighted MRI. ( 30773403 )
2019
24
Contralateral sensorineural hearing loss after vestibular schwannoma surgery. ( 29929725 )
2019
25
The prevalence of vestibular schwannoma among patients treated as sudden sensorineural hearing loss. ( 30042019 )
2019
26
Trigeminal neuralgia in vestibular schwannoma: Atypical presentation and neuroanatomical correlations. ( 30905383 )
2019
27
[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma. ( 31033921 )
2019
28
Surgical management of collision-tumors between vestibular schwannoma and meningioma in the cerebellopontine angle in patients with neurofibromatosis type 2. ( 31044279 )
2019
29
Pediatric intracranial lower cranial nerve schwannoma unassociated with neurofibromatosis type 2: case report and review of the literature. ( 30637480 )
2019
30
Intraoperative Monitoring of the Cochlear Nerve during Neurofibromatosis Type-2 Vestibular Schwannoma Surgery and Description of a "Test Intracochlear Electrode". ( 30723658 )
2019
31
Tumor-to-Tumor Metastasis From a Breast Carcinoma to a Vestibular Schwannoma. ( 30531647 )
2019
32
Cutaneous myxomas and a psammomatous melanotic schwannoma in a patient with Carney complex. ( 30632654 )
2019
33
Differentiation between intraspinal schwannoma and meningioma by MR characteristics and clinic features. ( 30684254 )
2019
34
Posterior tibial nerve schwannoma in a multiple myeloma patient: A case report. ( 31007915 )
2019
35
Differential Recovery in Early- and Late-Onset Delayed Facial Palsy Following Vestibular Schwannoma Resection. ( 31065704 )
2019
36
An international comparison of diagnostic and management strategies for vestibular schwannoma. ( 30421174 )
2019
37
Changing trends in management of vestibular schwannoma: A National Cancer Database study. ( 30450631 )
2019
38
Treatment of small and medium-sized vestibular schwannoma-a need for better evidence. ( 30467734 )
2019
39
Perioperative Recording of Cochlear Implant Evoked Brain Stem Responses After Removal of the Intralabyrinthine Portion of a Vestibular Schwannoma in a Patient with NF2. ( 30531638 )
2019
40
Brazilein induces apoptosis and G1/G0 phase cell cycle arrest by up-regulation of miR-133a in human vestibular schwannoma cells. ( 30610843 )
2019
41
A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. ( 30617350 )
2019
42
Tumor growth rate: A new prognostic indicator of hearing preservation in vestibular schwannoma surgery. ( 30623429 )
2019
43
Malignant Transformation of Vestibular Schwannoma after Stereotactic Radiosurgery. ( 30639496 )
2019
44
Ocular Tilt Reaction in Compensated Vestibular Schwannoma. ( 30640312 )
2019
45
Cochlear FLAIR Signal Changes in Hearing Preservation Vestibular Schwannoma Surgery. ( 30664035 )
2019
46
Prevalence of sporadic vestibular schwannoma: Reconciling temporal bone, radiologic, and population-based studies. ( 30688755 )
2019
47
Comparison of balance outcomes according to treatment modality of vestibular schwannoma. ( 30693520 )
2019
48
Management of jugular bulb injury during drilling of the internal auditory canal (ICA) for vestibular schwannoma surgery. ( 30704809 )
2019
49
Impact of Aspirin and Other NSAID Use on Volumetric and Linear Growth in Vestibular Schwannoma. ( 30717626 )
2019
50
Chances of Improvement in Cases of Vestibular Schwannoma Presenting with Facial Nerve Weakness: Presentation of Two Cases and Literature Review. ( 30733899 )
2019

Variations for Neurilemmoma

ClinVar genetic disease variations for Neurilemmoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SMARCB1 NM_003073.4(SMARCB1): c.*82C> T single nucleotide variant Pathogenic rs878854600 GRCh38 Chromosome 22, 23834262: 23834262
2 SMARCB1 NM_003073.4(SMARCB1): c.*82C> T single nucleotide variant Pathogenic rs878854600 GRCh37 Chromosome 22, 24176449: 24176449

Copy number variations for Neurilemmoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 163102 22 24129150 24176704 Deletion or amplific ation SMARCB1 Schwannoma

Expression for Neurilemmoma

Search GEO for disease gene expression data for Neurilemmoma.

Pathways for Neurilemmoma

GO Terms for Neurilemmoma

Cellular components related to Neurilemmoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ruffle GO:0001726 9.61 EZR NF2 S100B
2 apical part of cell GO:0045177 9.58 EZR MSN NF2
3 uropod GO:0001931 9.46 EZR MSN
4 microvillus GO:0005902 9.43 EZR MSN PDGFRA
5 astrocyte projection GO:0097449 9.37 EZR GFAP
6 invadopodium GO:0071437 9.32 EZR MSN
7 cell body GO:0044297 9.26 ACTC1 EZR GFAP NF2
8 filopodium GO:0030175 8.92 ACTC1 EZR MSN NF2
9 cytoplasm GO:0005737 10 ACTC1 ENO2 EZR GFAP KIT MSN

Biological processes related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 central nervous system development GO:0007417 9.76 NES S100B SOX10
2 negative regulation of apoptotic process GO:0043066 9.69 ACTC1 NGFR SOX10
3 negative regulation of protein kinase activity GO:0006469 9.67 NF1 NF2 PRKAR1A
4 cardiac myofibril assembly GO:0055003 9.61 ACTC1 PDGFRA
5 melanocyte differentiation GO:0030318 9.6 KIT SOX10
6 intermediate filament organization GO:0045109 9.59 GFAP VIM
7 astrocyte development GO:0014002 9.58 GFAP VIM
8 establishment of endothelial barrier GO:0061028 9.57 EZR MSN
9 establishment of epithelial cell apical/basal polarity GO:0045198 9.56 EZR MSN
10 positive regulation of cellular protein catabolic process GO:1903364 9.55 EZR MSN
11 positive regulation of myelination GO:0031643 9.54 S100B SOX10
12 positive regulation of phospholipase C activity GO:0010863 9.52 KIT PDGFRA
13 gland morphogenesis GO:0022612 9.48 EZR MSN
14 Bergmann glial cell differentiation GO:0060020 9.46 GFAP VIM
15 regulation of cell shape GO:0008360 9.46 EZR KIT MSN S100B
16 positive regulation of early endosome to late endosome transport GO:2000643 9.43 EZR MSN
17 negative regulation of neuron projection development GO:0010977 9.4 GFAP VIM
18 positive regulation of protein localization to early endosome GO:1902966 9.37 EZR MSN
19 membrane to membrane docking GO:0022614 9.32 EZR MSN
20 regulation of organelle assembly GO:1902115 9.26 EZR MSN
21 positive regulation of gene expression GO:0010628 9.1 ACTC1 EZR KIT MSN SOX10 VIM
22 intermediate filament-based process GO:0045103 8.96 GFAP VIM

Molecular functions related to Neurilemmoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of cytoskeleton GO:0005200 9.33 GFAP MSN VIM
2 S100 protein binding GO:0044548 9.26 EZR S100B
3 protein kinase A catalytic subunit binding GO:0034236 8.96 EZR PRKAR1A
4 cytoskeletal protein binding GO:0008092 8.8 EZR MSN NF2
5 protein binding GO:0005515 10.17 ENO2 EZR GFAP KIT MSN NF1

Sources for Neurilemmoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....